639 related articles for article (PubMed ID: 33168071)
1. Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis.
Raschi E; Privitera D; Bodio C; Lonati PA; Borghi MO; Ingegnoli F; Meroni PL; Chighizola CB
Arthritis Res Ther; 2020 Nov; 22(1):265. PubMed ID: 33168071
[TBL] [Abstract][Full Text] [Related]
2. Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts.
Raschi E; Chighizola CB; Cesana L; Privitera D; Ingegnoli F; Mastaglio C; Meroni PL; Borghi MO
Arthritis Res Ther; 2018 Aug; 20(1):187. PubMed ID: 30157947
[TBL] [Abstract][Full Text] [Related]
3. Antibodies against specific extractable nuclear antigens (ENAs) as diagnostic and prognostic tools and inducers of a profibrotic phenotype in cultured human skin fibroblasts: are they functional?
Corallo C; Cheleschi S; Cutolo M; Soldano S; Fioravanti A; Volpi N; Franci D; Nuti R; Giordano N
Arthritis Res Ther; 2019 Jun; 21(1):152. PubMed ID: 31234888
[TBL] [Abstract][Full Text] [Related]
4. From microvasculature to fibroblasts: Contribution of anti-endothelial cell antibodies in systemic sclerosis.
Corallo C; Franci B; Lucani B; Montella A; Chirico C; Gonnelli S; Nuti R; Giordano N
Int J Immunopathol Pharmacol; 2015 Mar; 28(1):93-103. PubMed ID: 25816411
[TBL] [Abstract][Full Text] [Related]
5. Toll-like receptor 3 upregulation by type I interferon in healthy and scleroderma dermal fibroblasts.
Agarwal SK; Wu M; Livingston CK; Parks DH; Mayes MD; Arnett FC; Tan FK
Arthritis Res Ther; 2011 Jan; 13(1):R3. PubMed ID: 21223583
[TBL] [Abstract][Full Text] [Related]
6. Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis.
Kim D; Peck A; Santer D; Patole P; Schwartz SM; Molitor JA; Arnett FC; Elkon KB
Arthritis Rheum; 2008 Jul; 58(7):2163-73. PubMed ID: 18576347
[TBL] [Abstract][Full Text] [Related]
7. Th17 cells favor inflammatory responses while inhibiting type I collagen deposition by dermal fibroblasts: differential effects in healthy and systemic sclerosis fibroblasts.
Brembilla NC; Montanari E; Truchetet ME; Raschi E; Meroni P; Chizzolini C
Arthritis Res Ther; 2013 Oct; 15(5):R151. PubMed ID: 24289089
[TBL] [Abstract][Full Text] [Related]
8. Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis.
Chizzolini C; Raschi E; Rezzonico R; Testoni C; Mallone R; Gabrielli A; Facchini A; Del Papa N; Borghi MO; Dayer JM; Meroni PL
Arthritis Rheum; 2002 Jun; 46(6):1602-13. PubMed ID: 12115192
[TBL] [Abstract][Full Text] [Related]
9. Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study.
Corallo C; Cutolo M; Kahaleh B; Pecetti G; Montella A; Chirico C; Soldano S; Nuti R; Giordano N
Arthritis Res Ther; 2016 Oct; 18(1):228. PubMed ID: 27716320
[TBL] [Abstract][Full Text] [Related]
10. Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis.
Kill A; Tabeling C; Undeutsch R; Kühl AA; Günther J; Radic M; Becker MO; Heidecke H; Worm M; Witzenrath M; Burmester GR; Dragun D; Riemekasten G
Arthritis Res Ther; 2014 Jan; 16(1):R29. PubMed ID: 24472528
[TBL] [Abstract][Full Text] [Related]
11. B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis.
François A; Chatelus E; Wachsmann D; Sibilia J; Bahram S; Alsaleh G; Gottenberg JE
Arthritis Res Ther; 2013 Oct; 15(5):R168. PubMed ID: 24289101
[TBL] [Abstract][Full Text] [Related]
12. 5-HT
Chaturvedi S; Misra DP; Prasad N; Rastogi K; Singh H; Rai MK; Agarwal V
Int J Rheum Dis; 2018 Dec; 21(12):2128-2138. PubMed ID: 30207074
[TBL] [Abstract][Full Text] [Related]
13. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations.
Gourh P; Arnett FC; Assassi S; Tan FK; Huang M; Diekman L; Mayes MD; Reveille JD; Agarwal SK
Arthritis Res Ther; 2009; 11(5):R147. PubMed ID: 19799786
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-35 is upregulated in systemic sclerosis and its serum levels are associated with early disease.
Tomcik M; Zerr P; Palumbo-Zerr K; Storkanova H; Hulejova H; Spiritovic M; Kodet O; Stork J; Becvar R; Vencovsky J; Pavelka K; Filkova M; Distler JH; Senolt L
Rheumatology (Oxford); 2015 Dec; 54(12):2273-82. PubMed ID: 26231346
[TBL] [Abstract][Full Text] [Related]
15. Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts.
Cipriani P; Di Benedetto P; Ruscitti P; Verzella D; Fischietti M; Zazzeroni F; Liakouli V; Carubbi F; Berardicurti O; Alesse E; Giacomelli R
Arthritis Res Ther; 2015 Sep; 17(1):247. PubMed ID: 26357964
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 and Type-I Collagen Production by Systemic Sclerosis Fibroblasts Are Differentially Regulated by Interleukin-17A in the Presence of Transforming Growth Factor-Beta 1.
Dufour AM; Alvarez M; Russo B; Chizzolini C
Front Immunol; 2018; 9():1865. PubMed ID: 30150989
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of the transforming growth factor β-inducible gene HIC-5 in systemic sclerosis skin and fibroblasts: a novel antifibrotic therapeutic target.
Piera-Velazquez S; Fertala J; Huaman-Vargas G; Louneva N; Jiménez SA
Rheumatology (Oxford); 2020 Oct; 59(10):3092-3098. PubMed ID: 32442272
[TBL] [Abstract][Full Text] [Related]
18. Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of toll-like receptor 4.
Fineschi S; Goffin L; Rezzonico R; Cozzi F; Dayer JM; Meroni PL; Chizzolini C
Arthritis Rheum; 2008 Dec; 58(12):3913-23. PubMed ID: 19035500
[TBL] [Abstract][Full Text] [Related]
19. Association of differentially expressed genes and autoantibody type in patients with systemic sclerosis.
Inamo J
Rheumatology (Oxford); 2021 Feb; 60(2):929-939. PubMed ID: 32911535
[TBL] [Abstract][Full Text] [Related]
20. Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis.
Manetti M; Romano E; Rosa I; Guiducci S; Bellando-Randone S; De Paulis A; Ibba-Manneschi L; Matucci-Cerinic M
Ann Rheum Dis; 2017 May; 76(5):924-934. PubMed ID: 28062404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
